Online inquiry

IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1126MR)

This product GTTS-WQ1126MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ1126MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9593MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ692MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA A-1230717
GTTS-WQ10175MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ13802MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-10933
GTTS-WQ15343MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ224MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ12025MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MM-302
GTTS-WQ15880MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XMT-1536
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW